Neuroprotective treatment for perinatal asphyxia.

Area of Science:

• Neonatal neurology
• Neuroprotection strategies
• Perinatal medicine

Background:

• Perinatal asphyxia poses significant risks to newborns, potentially leading to severe illness or death.
• The latent phase, occurring 6-24 hours post-hypoxic event, presents a critical window for intervention.
• Limiting neurological damage during this phase is crucial for improving infant outcomes.

Purpose of the Study:

• To review established and promising neuroprotective treatments for perinatal asphyxia.
• To identify interventions targeting cellular mechanisms of neurological damage.
• To evaluate strategies for limiting brain injury after hypoxic events.

Main Methods:

• Comprehensive literature search of Medline and Cochrane Library databases.
• Selection of 44 indexed, peer-reviewed original articles in English.
• Focus on neuroprotective treatment strategies for perinatal asphyxia.

Main Results:

• Hypothermia is the only treatment demonstrated to improve long-term outcomes in randomized clinical trials.
• Several potential treatments, including xenon gas, erythropoietin, and allopurinol, are currently under clinical investigation.
• Various treatments target diverse cellular mechanisms contributing to hypoxic-ischemic brain injury.

Conclusions:

• Further research is needed to assess the efficacy of xenon, erythropoietin, and allopurinol, particularly in combination with hypothermia.
• Future therapeutic avenues may include antioxidants, stem cell treatments, and DNA repair mechanisms.
• Optimizing neuroprotection in the latent phase holds potential for improved neurological recovery.